Last reviewed · How we verify
EI-001
EI-001 is an immunomodulatory agent that targets the PD-1/PD-L1 axis.
EI-001 is an immunomodulatory agent that targets the PD-1/PD-L1 axis. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic melanoma.
At a glance
| Generic name | EI-001 |
|---|---|
| Sponsor | Elixiron Immunotherapeutics (Hong Kong) Ltd. |
| Drug class | PD-1/PD-L1 inhibitor |
| Target | PD-1 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
EI-001 works by binding to PD-1 on T cells, preventing its interaction with PD-L1 on tumor cells, and thereby enhancing T cell-mediated anti-tumor responses. This mechanism is thought to be responsible for its therapeutic effects in various types of cancer.
Approved indications
- Metastatic non-small cell lung cancer, PD-L1 positive
- Metastatic melanoma
Common side effects
- Fatigue
- Diarrhea
- Nausea
Key clinical trials
- Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients (PHASE2)
- First in Human Study of EI-001 Monoclonal Antibody in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EI-001 CI brief — competitive landscape report
- EI-001 updates RSS · CI watch RSS
- Elixiron Immunotherapeutics (Hong Kong) Ltd. portfolio CI